Articles From: Tethys Petroleum Limited: New US$6 Million Loan Financing to Teva Launches Generic Diovan® in the United States


2015/1/16
http://www.ccnmatthews.com/logos/20090524-tethylo2.JPG GRAND CAYMAN, CAYMAN ISLANDS --
Sign-up for Tethys Petroleum Limited: New US$6 Million Loan Financing investment picks
2015/1/28
Tetra Tech, Inc. (NASDAQ: TTEK) today announced results for the fiscal 2015 first quarter ended December 28, 2014.
Sign-up for Tetra Tech Reports First Quarter Results investment picks
2015/2/17
Tetra Tech, Inc. (NASDAQ: TTEK) announced today that Dan Batrack, Chairman and CEO, will give a presentation to investors at the Baird Business Solutions Conference in New York on Tuesday, February 24, 2015, at 10:55 a.m. Eastern Time.
Sign-up for Tetra Tech to Present at the Baird Business Solutions Conference investment picks
2015/1/22
Tetra Tech, Inc. (NASDAQ: TTEK) announced today that it has been awarded a $185 million multiple award environmental remediation contract by the U.S. Army Corps of Engineers (USACE) Kansas City District.
Sign-up for Tetra Tech Wins $185 Million U.S. Army Environmental Remediation Contract investment picks
2015/2/4
THE WOODLANDS, Texas , Feb.
Sign-up for TETRA Technologies, Inc. Announces Date Of Annual Meeting Of Stockholders investment picks
2015/2/6
THE WOODLANDS, Texas , Feb.
Sign-up for TETRA Technologies, Inc. Announces Fourth Quarter 2014 Results Press Release And Conference Call Schedule investment picks
2015/2/27
THE WOODLANDS, Texas , Feb.
Sign-up for TETRA Technologies, Inc. Announces Fourth Quarter And Full Year 2014 Results investment picks
2015/1/26
THE WOODLANDS, Texas , Jan.
Sign-up for Tetra Technologies, Inc. Announces Leadership Change In Offshore Services Division investment picks
2014/12/16
THE WOODLANDS, Texas , Dec.
Sign-up for TETRA Technologies, Inc. Announces New Senior Vice President investment picks
2014/12/16
MALVERN, Pa., Dec.
Sign-up for TetraLogic Provides Update on Ovarian Cancer Study investment picks
2015/2/26
MALVERN, Pa., Feb.
Sign-up for TetraLogic Reports 2014 Financial Results and Provides Clinical Programs Update investment picks
2014/12/17
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced positive top-line results from IGNITE 1, the Company’s Phase 3 clinical trial of eravacycline for the treatment of complicated intra-abdominal infection (cIAI) compared to ertapenem.
Sign-up for Tetraphase Announces Positive Top-line Results from Phase 3 IGNITE 1 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections investment picks
2014/12/15
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , a clinical-stage biopharmaceutical company developing novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:^NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
Sign-up for Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index investment picks
2014/12/4
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic designed to be effective against multidrug-resistant bacteria, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer , will present at the Oppenheimer 25 th Annual Healthcare Conference on Thursday, December 11 at 1:00 p.m. Eastern Time.
Sign-up for Tetraphase Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference investment picks
2015/2/4
WATERTOWN, Mass., Feb.
Sign-up for Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences investment picks
2015/2/26
WATERTOWN, Mass., Feb.
Sign-up for Tetraphase to Host Conference Call Discussing Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights investment picks
2015/2/17
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva and Eagle Pharmaceuticals Announce Teva’s License to Commercialize Eagle’s Bendamustine Rapid Infusion Product investment picks
2015/2/12
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces $1 Billion Debt Tender Offer investment picks
2015/2/27
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Early Results of Debt Tender Offer, Pricing, Election of Early Settlement and Increase in Maximum Amount and Priority 2 Notes Tender Cap investment picks
2015/2/25
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the company’s hydrocodone bitartrate extended-release (ER) tablets formulated with Teva’s proprietary abuse deterrence technology (CEP-33237). CEP-33237 is an investigational, 12-hour, acetaminophen-free, formulation of extended-release hydrocodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Sign-up for Teva Announces FDA Acceptance for Review of NDA for its Investigational Twice-Daily Hydrocodone Bitartrate Extended-Release Tablets with Proprietary Abuse Deterrence Technology investment picks
2014/12/19
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) approved QNASL ® (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis (AR) in children 4-11 years of age.
Sign-up for Teva Announces FDA Approval of QNASL® (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis investment picks
2014/12/10
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Launch of First Generic Celebrex® Capsules in the United States investment picks
2015/2/24
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints investment picks
2015/3/2
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Sale of Sellersville, PA Facility investment picks
2015/1/20
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review investment picks
2015/2/17
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Bolsters Injectable Portfolio with Launch of Generic Lovenox® and Generic Zyvox® in the United States investment picks
2015/2/10
In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Files 2014 Annual Report on Form 20-F investment picks
2015/1/6
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Launches Generic Diovan® in the United States investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Tethys Petroleum Limited: New US$6 Million Loan Financing to Teva Launches Generic Diovan® in the United States
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent